Literature DB >> 10985775

Human AICAR transformylase: role of the 4-carboxamide of AICAR in binding and catalysis.

M Wall1, J H Shim, S J Benkovic.   

Abstract

We have prepared 4-substituted analogues of 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) to investigate the specificity and mechanism of AICAR transformylase (AICAR Tfase). Of the nine analogues of AICAR studied, only one analogue, 5-aminoimidazole-4-thiocarboxamide ribonucleotide, was a substrate, and it was converted to 6-mercaptopurine ribonucleotide. The other analogues either did not bind or were competitive inhibitors, the most potent being 5-amino-4-nitroimidazole ribonucleotide with a K(i) of 0.7 +/- 0.5 microM. The results show that the 4-carboxamide of AICAR is essential for catalysis, and it is proposed to assist in mediating proton transfer, catalyzing the reaction by trapping of the addition compound. AICAR analogues where the nitrogen of the 4-carboxamide was derivatized with a methyl or an allylic group did not bind AICAR Tfase, as determined by pre-steady-state burst kinetics; however, these compounds were potent inhibitors of IMP cyclohydrolase (IMP CHase), a second activity of the bifunctional mammalian enzyme (K(i) = 0.05 +/- 0.02 microM for 4-N-allyl-AlCAR). It is proposed that the conformation of the carboxamide moiety required for binding to AICAR Tfase is different than the conformation required for binding to IMP CHase, which is supported by inhibition studies of purine ribonucleotides. It is shown that 5-formyl-AICAR (FAICAR) is a product inhibitor of AICAR Tfase with K(i) of 0.4 +/- 0.1 microM. We have determined the equilibrium constant of the transformylase reaction to be 0.024 +/- 0.001, showing that the reaction strongly favors AICAR and the 10-formyl-folate cofactor. The coupling of the AICAR Tfase and IMP CHase activities on a single polypeptide allows the overall conversion of AICAR to IMP to be favorable by coupling the unfavorable formation of FAICAR with the highly favorable cyclization reaction. The current kinetic studies have also indicated that the release of FAICAR is the rate-limiting step, under steady-state conditions, in the bifunctional enzyme and channeling is not observed between AICAR Tfase and IMP CHase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985775     DOI: 10.1021/bi0007268

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

1.  Expression, purification, crystallization and preliminary X-ray diffraction crystallographic study of PurH from Escherichia coli.

Authors:  Xiaoting Qiu; Ye Yuan; Yongxiang Gao
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2011-11-26

2.  Structural analyses of a purine biosynthetic enzyme from Mycobacterium tuberculosis reveal a novel bound nucleotide.

Authors:  Jérôme Le Nours; Esther M M Bulloch; Zhening Zhang; David R Greenwood; Martin J Middleditch; James M J Dickson; Edward N Baker
Journal:  J Biol Chem       Date:  2011-09-28       Impact factor: 5.157

3.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

4.  Colocalization and Sequential Enzyme Activity in Aqueous Biphasic Systems: Experiments and Modeling.

Authors:  Bradley W Davis; William M Aumiller; Negar Hashemian; Songon An; Antonios Armaou; Christine D Keating
Journal:  Biophys J       Date:  2015-11-17       Impact factor: 4.033

5.  Aberrant cyclization affords a C-6 modified cyclic adenosine 5'-diphosphoribose analogue with biological activity in Jurkat T cells.

Authors:  Christelle Moreau; Tanja Kirchberger; Bo Zhang; Mark P Thomas; Karin Weber; Andreas H Guse; Barry V L Potter
Journal:  J Med Chem       Date:  2012-02-08       Impact factor: 7.446

6.  LD-aminopterin in the canine homologue of human atopic dermatitis: a randomized, controlled trial reveals dosing factors affecting optimal therapy.

Authors:  John A Zebala; Alan Mundell; Linda Messinger; Craig E Griffin; Aaron D Schuler; Stuart J Kahn
Journal:  PLoS One       Date:  2014-09-25       Impact factor: 3.240

7.  Impact of Variants in the ATIC and ARID5B Genes on Therapeutic Failure with Imatinib in Patients with Chronic Myeloid Leukemia.

Authors:  Karla Beatriz Cardias Cereja Pantoja; Tereza Cristina de Brito Azevedo; Darlen Cardoso de Carvalho; Natasha Monte; Amanda de Nazaré Cohen Paes; Maria Clara da Costa Barros; Lui Wallacy Morikawa Souza Vinagre; Ana Rosa Sales de Freitas; Rommel Mario Rodríguez Burbano; Paulo Pimentel de Assumpção; Sidney Emanuel Batista Dos Santos; Marianne Rodrigues Fernandes; Ney Pereira Carneiro Dos Santos
Journal:  Genes (Basel)       Date:  2022-02-10       Impact factor: 4.096

8.  Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerization.

Authors:  Ian B Spurr; Charles N Birts; Francesco Cuda; Stephen J Benkovic; Jeremy P Blaydes; Ali Tavassoli
Journal:  Chembiochem       Date:  2012-07-04       Impact factor: 3.164

Review 9.  Current Status of the Use of Multifunctional Enzymes as Anti-Cancer Drug Targets.

Authors:  Carla S S Teixeira; Sérgio F Sousa
Journal:  Pharmaceutics       Date:  2021-12-21       Impact factor: 6.321

Review 10.  Human de novo purine biosynthesis.

Authors:  Vidhi Pareek; Anthony M Pedley; Stephen J Benkovic
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-11-12       Impact factor: 8.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.